Sign in to view content

APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies

Michael J Allingham, MD, PhD

Video
Published 2021

Related

The Evolving Treatment of Proliferative Diabetic Retinopathy: The Diabetic Retinopathy Study to the DRCR Protocol S
Timothy W. Olsen, MD
Webinars and Journal Clubs
2016
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss
Jennifer K. Sun, MD
Updates from the Field
2019
Interaction of Genotypes and AREDS Formulation Use in the Development of Neovascular AMD
Pradeepa Yoganathan, MSc, MD, FRCS(C)
Annual Meeting Talks
2019

Category: Diabetic Retinopathy

See more